BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » Neural Stem Cells » Page 2

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

By

What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), almost 20 years since the discovery of human embryonic stem cells (hESC), and 10 years since the discovery of induced pluripotent stem cells (iPS cells). There are also more than 5,000 stem cell trials ongoing in clinics globally. Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics?

Stem Cell Therapeutics and Safe Practice

In this article:

Safety and Efficacy Issues with Stem Cell Therapies

In this novel and increasingly complex stem cell space, it is perhaps a timely question to ask, especially since the regulatory assessment criteria designed for conventional medicines are not directly applicable for stem cell therapy. [Read more…]

Genetically Modified Muscle Progenitor Cells with Stem Cell Medicine Ltd.

By

In the world of stem cells, there are a number of well-recognized market participants that receive a great deal of attention from the stem cell community.

At the same time, there are brilliant companies that quietly operate under the radar screen, building themselves up one intelligent and methodical step at a time. [Read more…]

Meet the New York Scientist Using Stem Cells as a Treatment For MS

By

Treatment for multiple sclerosis (MS) is an evolving area and one in which new therapeutic approaches are rapidly advancing. Led by Dr. Saud Sadiq, the Tisch MS Research Center of New York is pursuing a Phase II clinical trial exploring the use of stem cell technology for the treatment for MS. The announcement followed positive results from an FDA-approved Phase I stem cell trial for MS. [Read more…]

Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board

By

Montreal, Canada, May 4, 2017 – Fortuna Fix Inc., (“Fortuna”), a private, clinical-stage biotech company is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat neurodegenerative diseases. Fortuna announced today the launch of its Scientific Advisory Board (“SAB”) with Professor Michael Fehlings, MD, PhD, Father Kevin FitzGerald, S.J., PhD, COL (R) Dallas Hack, MD, MPH, and Professor James Giordano, PhD. [Read more…]

Stem Cell Research Products | Market Size, Segments, & Trends

By

“Stem Cell Research Products – Opportunities, Tools, & Technologies” is a global strategic report that evaluates opportunities across the entire stem cell product spectrum with an emphasis on opportunities for research product development.

Stem Cells Size | A Stem Cell Business Opportunity

In this article:

[Read more…]

BioInformant's World-Class Clients